AI, Radiology and Pet Care: Inside ASX’s Strongest IPO Pipeline in Four Years

AI, Radiology and Pet Care: Inside ASX’s Strongest IPO Pipeline in Four Years

More Deals, Bigger Deals

ASX has entered FY27 with its strongest IPO pipeline in four years, and the composition has shifted. The exchange describes the queue as increasingly weighted towards larger and more diverse transactions, rather than a rush of small resources shells. That distinction matters: a pipeline measured by proceeds and market capitalisation tells a different story from one measured simply by the number of names.

AI and Digital Infrastructure Lead

Artificial intelligence and digital infrastructure are the most visible themes. Firmus Technologies, an AI infrastructure company, has been repeatedly named as a likely 2026 ASX candidate. Morse Micro, a semiconductor specialist, and data-centre-linked assets are also in the conversation. Investor demand for AI exposure is strong, but ASX has relatively few pure-play listed vehicles compared with Nasdaq. A successful AI listing would give the local market a much-needed growth narrative beyond mining and financials.

Healthcare and Consumer Return

The pipeline is not only about technology. I-MED Radiology, one of Australia’s largest diagnostic imaging networks, and Greencross, the pets-and-vets business, have been flagged as potential debutants. GemLife Communities Group, the over-50s resort living provider, listed in 2025 with a $750 million raise at a $1.58 billion market capitalisation and returned 22 per cent, showing that large consumer-directed deals can clear the market when priced sensibly. Healthcare and consumer names bring earnings visibility that early-stage resources and technology often lack.

The Valuation Gap Remains the Brake

Fund managers are not uniformly optimistic. Wilson Asset Management’s Oscar Oberg has questioned whether the rate environment will support a bumper 2026, while TenCap’s Jun Bei Liu identified the gap between issuer expectations and investor willingness to pay as the biggest challenge. The RBA’s three rate hikes between February and May 2026 raised the discount rate applied to long-duration growth stocks, making valuation discipline more important than ever for AI and healthcare candidates.

Superannuation Is Both Buyer and Benchmark

The $4.4 trillion superannuation pool gives ASX a structural advantage in attracting large listings, but it also raises the bar. Fund managers can afford to wait for the right price and the right governance. For issuers, the message is that a listing is not an exit event; it is the beginning of a relationship with investors who will benchmark performance against global peers. The pipeline is the strongest in four years, but conversion into successful listings will depend on pricing, free float and aftermarket credibility.

Leave a Reply

Your email address will not be published. Required fields are marked *